Online Only Articles

Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort

Department of Hematology, Karolinska University Hospital, Stockholm;Department of Oncology-Pathology, Karolinska Institutet, Stockholm
Department of Hematology, Borås Hospital
Department of Oncology-Pathology, Karolinska Institutet, Stockholm
Department of Hematology, Lund University Hospital
Department of Hematology, Karolinska University Hospital, Stockholm;Department of Oncology-Pathology, Karolinska Institutet, Stockholm
Department of Hematology, Sunderby Hospital, Sunderbyn-Luleå
Department of Hematology, Karolinska University Hospital, Stockholm;Department of Oncology-Pathology, Karolinska Institutet, Stockholm
Department of Hematology, Uppsala University Hospital
Department of Internal Medicine, Karolinska Institutet, Stockholm
Department of Hematology, Linköping University Hospital
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm
Department of Radiation Sciences, Oncology, Umeå University, Sweden
Department of Hematology, Karolinska University Hospital, Stockholm;Department of Oncology-Pathology, Karolinska Institutet, Stockholm
Department of Hematology, Karolinska University Hospital, Stockholm;Department of Oncology-Pathology, Karolinska Institutet, Stockholm
Vol. 104 No. 5 (2019): May, 2019 https://doi.org/10.3324/haematol.2018.198820